Citadel Advisors’s Medifast MED Stock Holding History

Citadel Advisors’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$313K	Sell	30,700 -2,400	-7%	-$25.9K	﹤0.01%	10382
2025 Q4	$354K	Buy	33,100 +20,900	+171%	+$250K	﹤0.01%	9793
2025 Q3	$167K	Sell	12,200 -22,400	-65%	-$313K	﹤0.01%	11447
2025 Q2	$486K	Sell	34,600 -5,300	-13%	-$69.7K	﹤0.01%	8697
2025 Q1	$538K	Sell	39,900 -28,200	-41%	-$424K	﹤0.01%	8312
2024 Q4	$1.2M	Buy	68,100 +46,100	+210%	+$855K	﹤0.01%	6646
2024 Q3	$421K	Sell	22,000 -108,900	-83%	-$2.1M	﹤0.01%	8630
2024 Q2	$2.86M	Buy	130,900 +105,600	+417%	+$2.81M	﹤0.01%	4659
2024 Q1	$969K	Sell	25,300 -34,100	-57%	-$1.65M	﹤0.01%	6979
2023 Q4	$3.99M	Sell	59,400 -31,300	-35%	-$2.18M	﹤0.01%	4128
2023 Q3	$6.79M	Buy	90,700 +47,700	+111%	+$4.23M	﹤0.01%	3205
2023 Q2	$3.96M	Sell	43,000 -1,800	-4%	-$160K	﹤0.01%	4002
2023 Q1	$4.64M	Buy	44,800 +22,400	+100%	+$2.48M	﹤0.01%	3940
2022 Q4	$2.58M	Sell	22,400 -3,000	-12%	-$349K	﹤0.01%	5012
2022 Q3	$2.75M	Buy	25,400 +6,600	+35%	+$946K	﹤0.01%	4970
2022 Q2	$3.39M	Sell	18,800 -11,600	-38%	-$2.08M	﹤0.01%	4539
2022 Q1	$5.19M	Sell	30,400 -6,700	-18%	-$1.26M	﹤0.01%	4098
2021 Q4	$7.77M	Buy	37,100 +6,200	+20%	+$1.28M	﹤0.01%	3507
2021 Q3	$5.95M	Buy	30,900 +800	+3%	+$197K	﹤0.01%	3979
2021 Q2	$8.52M	Buy	30,100 +12,700	+73%	+$3.44M	﹤0.01%	3358
2021 Q1	$3.69M	Buy	17,400 +10,600	+156%	+$2.54M	﹤0.01%	4962
2020 Q4	$1.33M	Sell	6,800 -1,100	-14%	-$194K	﹤0.01%	6176
2020 Q3	$1.3M	Sell	7,900 -10,200	-56%	-$1.68M	﹤0.01%	5550
2020 Q2	$2.51M	Sell	18,100 -5,300	-23%	-$487K	﹤0.01%	4159
2020 Q1	$1.46M	Sell	23,400 -11,100	-32%	-$1.01M	﹤0.01%	4668
2019 Q4	$3.78M	Sell	34,500 -300	-0.9%	-$29K	﹤0.01%	3462
2019 Q3	$3.61M	Buy	34,800 +10,500	+43%	+$1.13M	﹤0.01%	3568
2019 Q2	$3.12M	Buy	24,300 +12,500	+106%	+$1.74M	﹤0.01%	3786
2019 Q1	$1.5M	Sell	11,800 -5,000	-30%	-$634K	﹤0.01%	4912
2018 Q4	$2.1M	Sell	16,800 -29,500	-64%	-$5.05M	﹤0.01%	4070
2018 Q3	$10.3M	Buy	46,300 +12,300	+36%	+$2.49M	﹤0.01%	2064
2018 Q2	$5.45M	Buy	34,000 +20,200	+146%	+$2.58M	﹤0.01%	2648
2018 Q1	$1.29M	Buy	13,800 +8,300	+151%	+$620K	﹤0.01%	4419
2017 Q4	$384K	Sell	5,500 -1,000	-15%	-$66.3K	﹤0.01%	6065
2017 Q3	$386K	Buy	+6,500	New	+$323K	﹤0.01%	5684
2016 Q1	–	Sell	-3,900	Closed	-$118K	–	7484
2015 Q4	$118K	Sell	3,900 -700	-15%	-$20.8K	﹤0.01%	6508
2015 Q3	$124K	Buy	4,600 +3,300	+254%	+$96.1K	﹤0.01%	6737
2015 Q2	$42K	Buy	1,300 +1,000	+333%	+$31.7K	﹤0.01%	7773
2015 Q1	$9K	Sell	300 -4,600	-94%	-$146K	﹤0.01%	8219
2014 Q4	$164K	Sell	4,900 -20,400	-81%	-$635K	﹤0.01%	6195
2014 Q3	$831K	Buy	25,300 +2,000	+9%	+$61.4K	﹤0.01%	3943
2014 Q2	$709K	Sell	23,300 -2,800	-11%	-$87.3K	﹤0.01%	3929
2014 Q1	$759K	Buy	26,100 +24,500	+1,531%	+$656K	﹤0.01%	3782
2013 Q4	$42K	Sell	1,600 -6,900	-81%	-$177K	﹤0.01%	6140
2013 Q3	$229K	Sell	8,500 -4,500	-35%	-$120K	﹤0.01%	4637
2013 Q2	$335K	Buy	+13,000	New	+$341K	﹤0.01%	4196

Other funds holding MED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SCP

Steamboat Capital Partners Rye, New York $403M AUM 43.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Citadel Advisors's MED Position: Q2 2025 in Review

Citadel Advisors sold out of Medifast (MED) in Q2 2025, closing a stake of 56,662 shares — an estimated $745K sold.

Citadel Advisors first reported a position in MED in Q2 2013 and held it in 45 quarters. The position peaked at $23.7M in Q2 2019. 120 funds tracked by Wall St. Rank hold MED as of Q2 2025.

Citadel Advisors reported no remaining Medifast position as of Q2 2025 after selling out during the quarter.
Citadel Advisors sold 56,662 Medifast shares in Q2 2025, an estimated $745K.
Citadel Advisors first reported a position in Medifast in Q2 2013 and held it in 45 quarters.
Citadel Advisors's Medifast position peaked at $23.7M in Q2 2019.
120 funds tracked by Wall St. Rank held Medifast as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.